The Centre again revised the gap between the 2 doses of Oxford-AstraZeneca’s Covishield – a COVID-19 vaccine manufactured by the Serum Institute of India (SII) last week.
At the start of the vaccination drive in January, the 2 doses were meant to be administered with a niche of four-six weeks. Later, the Centre revised it to four-eight weeks. Last week, it said that the doses of the vaccine are to be administered 12-16 weeks apart, following a recommendation by a government panel, saying it had been a “science-based decision”.
While the gap between inoculations of Covishield has been extended several times, it’s remained unchanged for Covaxin – developed by Bharat Biotech.
The reason behind the extension of the gap for Covishield but not for Covaxin, has been determined by the effectiveness of the primary dose of the vaccine, the Hindustan Times Indian Council of Medical Research (ICMR) chief Dr. Balaram Bhargava was quoted as saying.
According to Dr Bhargava, the administration of the primary dose of the Serum Institute’s vaccine leads to greater immunity, which remains effective for around 12 weeks. Therefore, it’s been decided to delay its second dose. However, that’s not the case with Indian Bharat Biotech’s vaccine, the report quoted the ICMR head as saying.